EQS-News: Marinomed Announces Strategic Expansion into Compounding Services Featuring Marinosolv® Technology
EQS-News: Marinomed Biotech AG / Key word(s): Expansion
Marinomed Announces Strategic Expansion into Compounding Services
Featuring Marinosolv® Technology
22.04.2026 / 09:04 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Announces Strategic Expansion into Compounding Services
Featuring Marinosolv® Technology
• Pharmaceutical compounding is a new business opportunity
• Marinosolv technology to play key role
• First steps initiated
Korneuburg, Austria, April 22^nd, 2026 Marinomed Biotech AG, a
healthcare-focused innovator committed to improving patient outcomes, (the
„Company“) today announced its strategic entry into the compounding
business. The company anticipates that several customers will commission
services based on the Marinosolv technology in the short to medium term.
First revenues are expected in Q4 2026 or beginning of 2027. The company
plans to cover its operating costs from its service business. This
expansion of its capabilities to deliver customized solutions based on its
Marinosolv technology tailored to the evolving needs of customers and
partners positions the company to meet growing global demand for
customized medicines tailored to individual patient needs, physician
preferences, and unmet therapeutic requirements.
By using Marinosolv technology, Marinomed will leverage advanced
solubilization capabilities that allow pharmacies a reproducible and
standardized process for producing compounded products effectively.
Technologies such as Marinosolv can be especially relevant in:
• Ophthalmic and ENT preparations
• Oral liquid formulations for poorly soluble APIs
• Topical and transdermal applications
• Rapid-onset specialty formulations
• Improved patient-friendly alternatives to conventional dosage forms
“Becoming a solution provider for compounding pharmacies opens an
additional, near-term business opportunity for Marinomed. We are convinced
that our technology and solutions can provide added value to the daily
work of pharmacists and the patients in need of personalized medicines,”
said Andreas Grassauer, CEO at Marinomed “Our platform allows us to unlock
new formulation possibilities and deliver solutions that go beyond the
limitations of standard, mass-produced products.”
Unlike conventional industrial products, which are manufactured in fixed
dosages and standardized formats for broad populations, compounded
formulations are tailored to specific patient or physicians´ needs. This
enables precise dosing and alternative delivery forms (such as liquids,
creams, or capsules). As a result, compounded medications can improve
adherence, tolerability, and overall outcomes—particularly in cases where
commercially available options fall short.
Compounded medications are commonly used in a variety of real-world
scenarios, including:
• Pediatrics: Creating child-friendly dosage forms, such as flavored
liquids, when standard tablets are unsuitable
• Geriatrics: Adjusting dosages or forms for patients with swallowing
difficulties or complex medication regimens
• Dermatology: Preparing personalized topical treatments with specific
concentrations or combinations of active ingredients
• Drug shortages or discontinued products: Recreating essential
medications that are temporarily or permanently unavailable
commercially
Key Territories Where Compounding Is Strategically Important
Marinomed intends to prioritize markets where compounding demand is
growing and healthcare systems value personalized treatment solutions.
Particularly in German-speaking countries compounding represents a
significant part of the business of pharmacies with Germany, Austria,
Switzerland (DACH) having strong pharmacy traditions, high regulatory
standards, and demand for magistral preparations. In addition, United
Kingdom shows a growing need for specialty manufacturing and customized
prescriptions as well as Nordics & Benelux – where an advanced healthcare
systems supports tailored patient care.
Quality, Compliance, and Strategic Partnerships
Marinomed stated that its compounding operations will be built on robust
quality systems, regulatory compliance, validated processes, and
partnerships with healthcare professionals, clinics, hospitals, and
technology providers.
The company will pursue opportunities in B2B supply partnerships while
investing in formulation R&D.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: [1] https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [2]pr@marinomed.com
E-Mail: [3]ir@marinomed.com
Disclaimer
The new shares and subscription rights have not been and will not be
registered under foreign securities laws – in particular under the U.S.
Securities Act of 1933, as amended („Securities Act“) – with foreign
securities authorities and may not be offered or sold, in particular in
the United States of America („US“), without registration or an exemption
from the registration requirements under the Securities Act. This
communication is not intended for distribution to or within the US and may
not be distributed or forwarded to publications with general circulation
in the US. This communication constitutes neither an offer to sell nor an
invitation to subscribe for or purchase securities in any jurisdiction in
which such an offer or such an invitation would be unlawful.
══════════════════════════════════════════════════════════════════════════
22.04.2026 CET/CEST This Corporate News was distributed by [4]EQS Group
View original content: [5]EQS News
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
Market)
EQS News ID: 2312604
End of News EQS News Service
2312604 22.04.2026 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2312604&application_name=news&site_id=apa_ots_austria~~
References
~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. pr@marinomed.com
3. ir@marinomed.com
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2312604&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cbdaa3a04d625c5aa141d10512c94b66&application_id=2312604&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender